Clinical trials: Sclerosis, Progressive Systemic
Diffuse Cutaneous Systemic Sclerosis
A Study of Subcutaneous Abatacept to Treat Diffuse Cutaneous Systemic Sclerosis
The study hypothesis is that SC abatacept is safe and shows evidence of efficacy (improvement in modified Rodnan score [mRSS]) in patients with diffuse cutaneous systemic sclerosis (dcScc) compared to matching placebo.
- Trial name
- ASSET (NCT02161406)
- Testing
- Abatacept
- Where
- 27 sites in United States, Canada and 1 more
- Volunteers
- 88 people
- Sponsor
- Dinesh Khanna, MD, MS
Scleroderma
A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This is a two part study. The purpose of Part A is to determine if BMS-986020 is effective in treatment of diffuse cutaneous systemic sclerosis using one dose of BMS-986020.
- Trial name
- NCT02588625
- Testing
- BMS-986020
- Where
- 27 sites in United States, Canada and 2 more
- Sponsor
- Bristol-Myers Squibb
Systemic Sclerosis
Phase II Study of Recombinant Relaxin for Progressive Systemic Sclerosis
OBJECTIVES: I. Determine whether parenteral relaxin improves skin tightness, Raynaud's phenomenon, digital morbidity, and digital ulcers in a patient with progressive systemic sclerosis (scleroderma). II.
- Trial name
- NCT00004380
- Testing
- relaxin
- Volunteers
- 1 people
- Sponsor
- National Center for Research Resources (NCRR)
Diffuse Cutaneous Systemic Sclerosis
Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic Sclerosis
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and efficacy of JBT-101 in adult subjects with diffuse cutaneous systemic sclerosis.
- Trial name
- NCT02465437
- Testing
- JBT-101, Part B Open-Label Extension
- Where
- 9 sites in United States
- Volunteers
- 42 people
- Sponsor
- Corbus Pharmaceuticals Inc.
Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
CARTIMMUNE: Study of Patients With Autoimmune Diseases Receiving KYV-101
The purpose of this study is to assess the safety, tolerability, and clinical activity of KYV 101 (a fully-human anti-CD19 CAR T-cell therapy) in adult subjects with B cell-driven autoimmune diseases.
- Conditions
- Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis, SLE Nephritis, ANCA Associated Vasculitis
- Trial name
- CARTIMMUNE (NCT06152172)
- Testing
- KYV-101, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- David Porter
Diffuse Cutaneous Systemic Sclerosis
Mycophenolate Mofetil in Systemic Sclerosis
This is a research study of an investigational product called Mycophenolate mofetil (MMF). The study is designed to establish the safety and potential benefit of MMF.
- Trial name
- NCT00433186
- Testing
- Mycophenolate Mofetil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Boston University
SSc-Systemic Sclerosis
Safety, Efficacy and Cellular Metabolic Dynamics of CT1195E in Patients With Refractory / Progressive SSC
This study is a single arm, open label, exploratory dose escalation clinical study to evaluate the safety, efficacy, and cellular metabolic dynamics of ct1195e cells in patients with SSc.
- Trial name
- NCT07355972
- Testing
- CAR-T Therapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Systemic Sclerosis
The Safety and Efficacy of Telitacicept in the Treatment of Systemic Sclerosis
Systemic sclerosis (SSc) is a chronic, multisystem autoimmune disease characterized by potentially widespread and progressive skin fibrosis and vascular abnormalities, and may involve the musculoskeletal, gastrointestinal…
- Trial name
- NCT06546540
- Testing
- Telitacicept
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
Systemic Lupus Erythematosus, Lupus Nephritis
A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases
CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic…
- Conditions
- Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis
- Trial name
- CALiPSO-1 (NCT06255028)
- Testing
- CNTY-101, IL-2, Lymphodepleting Chemotherapy
- Where
- 6 sites in United States
- Volunteers
- 6 people
- Sponsor
- Century Therapeutics, Inc.
Systemic Sclerosis (SSc)
The Effect of Progressive Muscle Relaxation Exercises on Fatigue, Dyspnea, and Respiratory Function in Patients With Systemic Sclerosis
This study aims to evaluate the effects of progressive muscle relaxation exercises on fatigue, dyspnea, and respiratory function in patients with systemic sclerosis. Participants will be assessed before and after the intervention.
- Trial name
- PMR-SCLERODERM (NCT07842133)
- Testing
- Progressive Muscle Relaxation Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 50 people
- Sponsor
- University of Gaziantep
Limited Scleroderma, Diffuse Scleroderma
A Non-Interventional Pilot Study Assessing Whether Lysyl Oxidase-like 2 (LOXL2) is Present in Subjects With Scleroderma
To treat patients with scleroderma by blocking the expression of LOXL2. The investigators first need to confirm (through observation) that LOXL2 is overexpressed in disease.
- Trial name
- NCT01881529
- Where
- Australia
- Volunteers
- 29 people
- Sponsor
- Gilead Sciences
Systemic Sclerosis, Scleroderma
Evaluation of Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis (dcSSc)
This Phase I/II placebo controlled trial will evaluate tofacitinib in subjects with diffuse cutaneous systemic scleroderma (dcSSc).
- Trial name
- TOFA-SSc (NCT03274076)
- Testing
- Tofacitinib
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- University of Michigan
Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD)
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
This is a prospective, single-arm, open-label dose-escalation clinical study to evaluate LVIVO-TaVec400 in the treatment of relapsed/refractory autoimmune diseases.
- Conditions
- Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Progressive Multiple Sclerosis (PMS), Relapsed/Refractory Myasthenia Gravis(r/r MS)
- Trial name
- NCT07583030
- Testing
- LVIVO-TaVec400 product
- Where
- 4 sites in China
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Diffuse Systemic Sclerosis
Serial Night Time Position Splint on Systemic Sclerosis
This is a randomized controlled trial with blinded evaluator and follow-up of one year. Seventy six patients with diffuse systemic sclerosis, will be randomized into two groups.The patients can not change their medication during…
- Trial name
- NCT01586663
- Testing
- Serial night time position splint, Drug treatment
- Where
- Brazil
- Volunteers
- 76 people
- Sponsor
- Federal University of São Paulo
Interstitial Lung Disease
Pulmonary Care and Research Collaborative Patient Registry
The purpose of this research study is to build and maintain a registry of people with interstitial lung disease (ILD). Medical information collected for this registry may be used to advance ILD and pulmonary research and improve…
- Trial name
- NCT05445817
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Systemic Sclerosis
Recombinant Human Relaxin in the Treatment of Diffuse Scleroderma
Relaxin is a naturally occurring protein prduced by the ovary or placenta in pregnancy. It has ani-fibrotic properties. Previous studies have shown that relaxin is safe at concentrations upto 60 times higher than achieved in…
- Trial name
- NCT00704665
- Testing
- Relaxin
- Volunteers
- 231 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Systemic Sclerosis
Phase II Pilot Study of Cyclophosphamide and Rabbit Anti-Thymocyte Globulin as Salvage Therapy in Patients With Diffuse Systemic Sclerosis
OBJECTIVES: I. Determine the toxicity of cyclophosphamide and rabbit anti-thymocyte globulin in patients with diffuse systemic sclerosis. II.
- Trial name
- NCT00016458
- Testing
- anti-thymocyte globulin, cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fred Hutchinson Cancer Center
Systemic Sclerosis
Prednisolone in Early Diffuse Systemic Sclerosis
This is a randomised placebo-controlled study of moderate dose prednisolone for 6 months in patients with early diffuse cutaneous systemic sclerosis (dcSSc).
- Trial name
- PRedSS (NCT03708718)
- Testing
- Prednisolone 5 mg
- Where
- 14 sites in United Kingdom
- Volunteers
- 35 people
- Sponsor
- Prof. Ariane herrick
Lung Diseases, Interstitial, Lung Disease With Systemic Sclerosis
Non-interventional Study Describing Epidemiology, Prognosis and Patient Healthcare Costs in France, 2010-2017
Interstitial lung diseases (ILDs) are a heterogeneous group of disorders, which encompass a wide range of conditions. In some patients with fibrosing ILDs, a progressive phenotype similar to that observed in idiopathic pulmonary…
- Trial name
- PROGRESS (NCT03858842)
- Testing
- epidemiology, healthcare costs in non-IPF PF-ILD and SSc-ILD
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Scleroderma, Diffuse
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis…
- Trial name
- NCT06655896
- Testing
- rapcabtagene autoleucel, rituximab
- Where
- 93 sites in United States, Argentina and 20 more
- Volunteers
- 96 people
- Sponsor
- Novartis Pharmaceuticals